Daily Market Research Report

October 24, 2025

Alpha Signal Monitor

Welcome to your daily pre-market briefing. This report provides key insights on market opportunities and analyst perspectives to help identify potential alpha signals.

Today's Coverage: - IPO Calendar: Upcoming initial public offerings and market debuts - Stock Ratings: Latest analyst ratings and target prices for our watchlist

Watchlist Stocks: AAPL, MSFT, GOOGL, AMZN, NVDA, META, TSLA

This report is generated using advanced AI research capabilities with real-time market data access.

IPO Calendar

Timeframe: October 24, 2025 to November 24, 2025

The next month features a mix of larger operating-company IPOs (software/fintech, aerospace, diagnostics) alongside biotechs and a few micro-caps. Several issuers are using Section 8(a)’s automatic effectiveness language to proceed during the government shutdown, setting price terms ~20 days before listing; expect dates to remain fluid. Notable deals include Navan (travel/expense software), BETA Technologies (electric aircraft), Exzeo (insurtech carve-out), and BillionToOne (molecular diagnostics), with continued biotech activity from MapLight and Evommune. Overall issuance is picking up from earlier in the year, though week-to-week timing may shift with market conditions. citeturn18news12turn17news12turn19search9turn0search1

MapLight Therapeutics, Inc. (MPLT)

• Expected listing date: 2025-10-28
• Price range: $17.00 (fixed)
• Shares offered: 14,750,000 primary shares; 30-day option for up to 2,212,500 additional shares
• Exchange: Nasdaq Global Market
• Lead underwriters: Morgan Stanley, Jefferies, Leerink Partners, Stifel
• Business summary: Clinical-stage biotech developing circuit-specific therapies for central nervous system disorders; lead programs include ML-007C-MA and ML-004. citeturn16news12
• Notes: Company announced a concurrent private placement of 476,707 shares to Goldman Sachs affiliates at the IPO price; registration includes language for automatic effectiveness under Section 8(a). Timing and allocations may shift with market conditions. citeturn16search0turn16search2
• Sources: SEC Form S-1/A filed Oct 6, 2025 (MapLight Therapeutics, Inc.), PR Newswire: “MapLight Therapeutics Announces Commencement of Initial Public Offering” (Oct 6, 2025), Reuters: “Drug developer MapLight eyes $704.3 million valuation in US IPO” (Oct 6, 2025)

HW Electro Co., Ltd. (HWEP)

• Expected listing date: 2025-10-30
• Price range: $4.00 per ADS
• Shares offered: 4,150,000 ADS; 30-day option up to 622,500 ADS
• Exchange: Nasdaq Capital Market
• Lead underwriters: American Trust Investment Services, WestPark Capital
• Business summary: Japan-based seller of electric light commercial vehicles (ELEMO series), produced with a partner manufacturer; early-stage revenues and micro-cap size. citeturn9search6
• Notes: Registration declared effective June 30, 2025; post-effective amendment filed Sept 18, 2025. Small-cap offerings like this often adjust timing near launch. citeturn9search1turn9search5
• Sources: SEC Form F-1/A and related correspondence (June 2 & June 23, 2025), SEC Post-Effective Amendment (Sept 18, 2025), DefenseWorld/IPO Scoop calendar note on bookrunners and timing (Sept–Oct 2025)

Navan, Inc. (NAVN)

• Expected listing date: 2025-10-31
• Price range: $24.00 – $26.00
• Shares offered: 36,924,406 shares (30,000,000 primary; 6,924,406 secondary); 30-day option up to 5,538,660
• Exchange: Nasdaq Global Select Market
• Lead underwriters: Goldman Sachs, Citigroup, Jefferies, Mizuho, Morgan Stanley
• Business summary: AI-enabled platform for corporate travel, payments, and expense management; public filing shows strong recent growth with ongoing losses as it scales. citeturn18news12
• Notes: Roadshow launched Oct 21, 2025; deal proceeding with automatic-effectiveness language amid the shutdown. Final pricing, allocations, and date may change. citeturn18search0
• Sources: Company press release: Roadshow launch (Oct 21, 2025), Company press release: S-1 filing and proposed Nasdaq symbol (Sept 19, 2025), Reuters: valuation/terms and timing (Oct 10, 2025)

Nomadar Corp. (NOMA)

• Expected listing date: 2025-10-31
• Shares offered: 13,268,718 Class A shares registered for resale in connection with a direct listing
• Exchange: Nasdaq Capital Market
• Business summary: US-based company affiliated with Cádiz CF’s Sportech; proposed business spans sports/tourism infrastructure, training programs, and brand extensions. citeturn10search1
• Notes: Direct listing (not a firm-commitment IPO); no traditional bookrunners. Listing remains contingent on Nasdaq approval and market readiness; date is estimated on calendars. citeturn10search6turn10search4
• Sources: SEC: S-1/A (Sept–Oct 2025 amendments), PR Newswire: Investor webinar announcement (Oct 21, 2025), StockAnalysis issuer profile/calendar (Oct 2025)

BETA Technologies, Inc. (BETA)

• Expected listing date: 2025-11-03
• Price range: $27.00 – $33.00
• Shares offered: 25,000,000 Class A shares; 30-day option up to 3,750,000; cornerstone indications up to $300 million
• Exchange: NYSE
• Lead underwriters: Morgan Stanley, Goldman Sachs, BofA Securities, Jefferies, Citigroup, Cantor, BTIG, Needham & Company
• Business summary: Developer of electric aircraft, propulsion systems, and charging infrastructure; targeting commercial missions across cargo, medevac, and passenger use cases. citeturn17news12
• Notes: Using Section 8(a) automatic effectiveness; listing date targeted for early November subject to market conditions. citeturn17search5
• Sources: SEC: S-1 (Sept 29, 2025) and S-1/A (Oct 15, 2025), Reuters: valuation, terms, and cornerstone indications (Oct 15, 2025), Vermont Business Magazine/Business Wire: roadshow launch (Oct 15–16, 2025)

Exzeo Group, Inc. (XZO)

• Expected listing date: 2025-11-05
• Price range: $20.00 – $22.00
• Shares offered: 8,000,000 shares; 30-day option up to 1,200,000
• Exchange: NYSE
• Lead underwriters: Truist Securities, Citizens Capital Markets, William Blair, Fifth Third Securities (co-manager)
• Business summary: Insurtech platform (carve-out of HCI Group) offering P&C carriers software for underwriting, policy administration, claims, analytics, and reporting. citeturn19search9
• Notes: Registration includes Rule 473(b) language for automatic effectiveness on or about Nov 4, 2025; HCI Group to retain a majority stake. Timing subject to market conditions. citeturn19search0
• Sources: HCI Group press release: Exzeo launches IPO (Oct 16, 2025), Renaissance Capital: terms set for $168m IPO (Oct 16, 2025), Reuters: valuation/terms context (Oct 16, 2025)

BillionToOne, Inc. (BLLN)

• Expected listing date: 2025-11-06
• Price range: $49.00 – $55.00
• Shares offered: 3,846,000 shares (primary)
• Exchange: Nasdaq Global Select Market
• Lead underwriters: J.P. Morgan, Piper Sandler, Jefferies, William Blair, Stifel, Wells Fargo Securities, BTIG
• Business summary: Molecular diagnostics company with prenatal (UNITY) and oncology liquid biopsy (Northstar) tests built on a single‑molecule NGS platform. citeturn20search4
• Notes: Issuer removed the delaying amendment and is proceeding via automatic effectiveness during the shutdown; pricing expected the evening before listing but may shift. citeturn20search0turn20search3
• Sources: SEC Form S-1/A filed Oct 17, 2025 (BillionToOne, Inc.), Renaissance Capital: terms set for ~$200m IPO (Oct 17, 2025), Reuters: filing and revenue growth context (Oct 7 & 17, 2025)

Evommune, Inc. (EVMN)

• Expected listing date: 2025-11-07
• Price range: $15.00 – $17.00
• Shares offered: 9,375,000 shares
• Exchange: NYSE
• Lead underwriters: Morgan Stanley, Leerink Partners, Evercore ISI, Cantor
• Business summary: Biotech developing therapies for chronic inflammatory diseases; lead oral MRGPRX2 antagonist (EVO756) in Phase 2b for chronic spontaneous urticaria and atopic dermatitis. citeturn6search3
• Notes: Filing uses automatic effectiveness language to navigate the shutdown; dates and size may change at pricing. citeturn6search2
• Sources: SEC: Form S-1 (Oct 2025) and subsequent amendments, Renaissance Capital: terms set for ~$150m IPO (Oct 17, 2025)

DT House Limited (DTDT)

• Expected listing date: 2025-10-28
• Price range: $4.00 – $5.00
• Shares offered: 2,000,000 shares (plus customary 15% option)
• Exchange: Nasdaq Capital Market
• Lead underwriters: American Trust Investment Services
• Business summary: Cayman holding company with subsidiaries in the UAE and Hong Kong providing ESG-focused corporate consultancy; recently added UAE leisure travel services. citeturn15search6
• Notes: A small-cap offering whose date has shifted on calendars (Oct 23–28 range); confirm final terms in the prospectus/424B at pricing. citeturn15search4
• Sources: Renaissance Capital: initial filing/terms (Mar 3, 2025), DefenseWorld/IPO Scoop calendar update (Oct 16, 2025), StockAnalysis IPO calendar (Oct 2025)

Dates and terms frequently change—especially for smaller deals and during the shutdown-period workaround using Section 8(a). Final pricing, allocations, and listing venues are set at pricing and exchange approval; monitor the final prospectus (424B) and exchange notices on the day of listing for definitive details. citeturn17news12turn19search9

Stock Ratings

Error retrieving stock ratings information: Connection error.

Disclaimer

This research report is for informational purposes only and does not constitute investment advice. All information is sourced from publicly available data and should be verified independently. Past performance does not guarantee future results.

Generated on: 2025-10-24 at 11:28 UTC
Source: Alpha Signal Monitor - Automated Research System
Contact: For questions about this report, please contact your Alpha Signal Monitor administrator.

Powered by Alpha Signal Monitor | Market Intelligence Through AI